Stephen E Webber

Founder at Primmune Therapeutics, Inc.

Commercial Services

Profile

Stephen E Webber is the Vice President-Medicinal Chemistry and founder of Primmune Therapeutics, Inc. founded in 2017.
Mr. Webber is also the founder of eFFECTOR Therapeutics Operations, Inc.

Stephen E Webber active positions

Companies	Position	Start
Primmune Therapeutics, Inc. Primmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA.	Founder	30/09/2017

All active positions of Stephen E Webber

Former positions of Stephen E Webber

Companies	Position	End
eFFECTOR Therapeutics Operations, Inc. eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA.	Founder	-

See the detail of Stephen E Webber's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Stephen E Webber's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
eFFECTOR Therapeutics Operations, Inc. eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA.	Commercial Services
Primmune Therapeutics, Inc. Primmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA.	Commercial Services